Nevertheless, preclinical studies evidencing an in vitro synergy between first-generation inhibitors and chemotherapy in suppressing FLT3 mutant AML cells [50,51] supported further clinical trials. This evidence concerns the gene FLT3 and acute myeloid leukemia.